01377nas a2200217   4500000000100000008004100001653001100042653001200053653001200065653002800077100001300105700001400118700001400132700001500146700002800161245012700189856005100316300001200367490000700379520077300386       2018                            d10aBrazil10aDapsone10aleprosy10aMultidrug therapy (MDT)1 aPante CC1 aCoelho SC1 aCarelli L1 aAvancini J1 aBianconcini Trindade MA00aSevere adverse reactions to multidrug therapy for leprosy, registered in tertiary services between 2012 and 2017 in Brazil  uhttps://leprosyreview.org/article/89/4/32-8334  a328-3340 v893 a<p><em>Objectives:</em> This work aims to determinate the main severe adverse reactions to multidrug therapy (MDT), as well as the characteristics of the patients who had them and the period when they were more prevalent.<br />
<em>Results:</em> Of the 158 patients undergoing treatment for leprosy in the period 2012–2017, 22 (13·9%) were using substitutive treatment for leprosy and presented criteria to enter this study. Adverse reactions were more frequent in women (59·1%), above 45 years age and during second month of treatment. Dapsone was the most frequently implied drug (86·4%), and hemolytic anemia was the main reaction (72·7%).<br />
<em>Conclusion:</em> Severe adverse reaction to dapsone is common in MDT, mainly due to hemolytic anemia.</p>